logo

Akebia Therapeutics, Inc. (AKBA)



Trade AKBA now with
  Date
  Headline
2/22/2022 8:37:34 AM Akebia Announces Amendment Of License Agreement With Vifor Pharma In Preparation For Potential Vadadustat Launch
11/4/2021 8:09:53 AM Akebia Therapeutics Q3 Net Loss $59.5 Mln Vs Net Loss $60.0 Mln Last Year
11/1/2021 8:09:43 AM Akebia Therapeutics Says Appoints Ron Frieson To Its Board Of Directors
10/29/2021 8:04:42 AM Akebia Announces Otsuka's Submission Of Initial MAA To EMA For Vadadustat For Anemia Due To Chronic Kidney Disease
10/18/2021 8:13:47 AM Akebia Says Vadadustat Efficacy And Safety Data To Be Presented At American Society Of Nephrology Kidney Week 2021
8/5/2021 8:00:24 AM Akebia Therapeutics Q2 Net Loss $83 Mln Vs $175.8 Mln Last Year
6/3/2021 8:15:34 AM Akebia Therapeutics Presents Data From Phase 3 Program For Vadadustat At European Renal Association
6/1/2021 6:02:43 AM Akebia, Otsuka: FDA Accepts NDA Filing For Vadadustat ForAnemia Due To CKD In Patients On Dialysis & Not On Dialysis
3/30/2021 6:02:23 AM Akebia Submits NDA To FDA For Vadadustat
3/24/2021 8:09:54 AM Akebia Reports Approval For Addl Indication Of Riona For Treatment Of Iron Deficiency Anemia In Adult Patients In Japan
2/25/2021 8:46:00 AM Akebia Q4 Total Revenue $56.7 Mln Vs. $69.6 Mln Prior Year
11/7/2014 9:36:09 AM Nomura Reiterates Akebia Therapeutics, Inc. (AKBA) At Buy With $39 Price Target
4/14/2014 10:51:24 AM Nomura Initiates Akebia Therapeutics, Inc. (AKBA) At Buy With $39 Price Target